ArticleThoracic cancer2020
MiRNA-96-5p impacts the progression of breast cancer through targeting FOXO3.
Article in Thoracic cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 34 citations in OpenAlex.
- Berberine Modulates Mitophagy-Related Gene Expression and Suppresses Breast Cancer Cells: A Multi-Omics and Experimental Study.Cell biochemistry and biophysics · 2026Article
- Extracellular vesicles in nipple discharge for breast cancer screening.Breast cancer research and treatment · 2026Article
- Integrative Machine Learning Model for Overall Survival Prediction in Breast Cancer Using Clinical and Transcriptomic Data.Biology · 2025Article
- MicroRNA‑96 promotes the proliferation and migration of breast cancer cells by inhibiting Smad7 expression.Oncology letters · 2025Article
- A novel necroptosis-related miRNA signature for predicting the prognosis of esophageal cancer and immune infiltration analysis.Translational cancer research · 2025Article
- Ssc-miR-101-3p inhibits hypoxia-induced apoptosis and inflammatory response in alveolar type-II epithelial cells of Tibetan pigs via targeting FOXO3.Scientific reports · 2024Article
- Identification of a glycolysis-related miRNA Signature for Predicting Breast cancer Survival.Molecular biotechnology · 2024Article
- Unravelling the therapeutic potential of forkhead box proteins in breast cancer: An update (Review).Oncology reports · 2024Review
- Epigenetic disruption of the RARγ complex impairs its function to bookmark AR enhancer interactions required for enzalutamide sensitivity in prostate cancer.bioRxiv : the preprint server for biology · 2024Article
- Insulin Resistance in Pediatric Obesity: From Mechanisms to Treatment Strategies.Pediatric diabetes · 2024Review
- Role and regulation of FOXO3a: new insights into breast cancer therapy.Frontiers in pharmacology · 2024Review
- The Involvement of Peroxiporins and Antioxidant Transcription Factors in Breast Cancer Therapy Resistance.Cancers · 2023Review
- Knockdown of circADAM9 inhibits cell progression and glycolysis by targeting the miR-1236-3p/FGF7 axis in breast cancer.Thoracic cancer · 2023Article
- Value of negatively correlated miR-205-5p/Cancer pathogenesis and therapy · 2023Article
- Circular RNA circ_0048764 promotes the development of breast cancer by regulating microRNA-1296-5p/tripartite motif containing 14 axis.Bioengineered · 2022Article
- NR2F1-AS1 Acts as an Oncogene in Breast Cancer by Competitively Binding with miR-641.Journal of healthcare engineering · 2022Article
- MicroRNA-96: A therapeutic and diagnostic tumor marker.Iranian journal of basic medical sciences · 2022Review
- Hypoxic Breast Cancer Cell-Derived Exosomal SNHG1 Promotes Breast Cancer Growth and Angiogenesis via Regulating miR-216b-5p/JAK2 Axis.Cancer management and research · 2022Article
- The Epigenetic Regulation of Nonhistone Proteins by SETD7: New Targets in Cancer.Frontiers in genetics · 2022Review
- Long non-coding RNA ARAP1-AS1 contributes to cell proliferation and migration in clear cell renal cell carcinoma via the miR-361-3p/placental growth factor axis.Bioengineered · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBreast cancer is the most common malignant tumor in women worldwide, with a high mortality rate. MicroRNAs are small non-coding RNAs that negatively regulate the expression of target genes by interacting with the target gene 3'-UTR, and participate in cell differentiation, proliferation, apoptosis and metabolism. The function of miRNA-96-5p in the progression of breast cancer has not been reported.
methodsWe used the StarBase database to investigate the expression of miRNA-96-5p in breast cancer and adjacent normal tissues. FOXO3 3'-UTR construct and luciferase reporter assays was performed for the target gene. Expression levels of miRNAs including its target were analyzed by qRT-PCR and western blot. Cell proliferation was detected by CCK8 and colony formation, EdU assay.
resultsLuciferase reporter assays showed miRNA-96-5p directly targeted FOXO3. Abrogation of miRNA-96-5p by transfection with its inhibitors in breast cancer cells significantly suppressed miRNA-96-5p expression and breast cancer cells proliferation. Western blot revealed that overexpression of miRNA-96-5p substantially reduced FOXO3 protein expression. We used the GEPIA, UALCAN and KM-plotter databases to investigate the expression of FOXO3 in human breast cancer and adjacent normal tissues, and its correlation with survival. In addition, we found that FOXO3 spoiled miR-96-5p induced breast cancer cell proliferation block effecting.
conclusionsmiRNA-96-5p may exert a tumor promotion role through negatively regulating tumor suppressor gene FOXO3 and promoting cell proliferation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.